Skip to main content
medichelpline
Join Free
Back to Drug Index
General MedicationsINTRAMUSCULAR, SUBCUTANEOUSGeneric

BRAVELLE

UROFOLLITROPIN

Standard Dose
75 IU/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued

Key Takeaways

  • Primary indication: Review priority: STANDARD Marketing status: Discontinued
  • Approval overview BRAVELLE is listed in Drugs@FDA under application 021289 (BLA).
  • Review priority: STANDARD Marketing status: Discontinued Active ingredient UROFOLLITROPIN Form and strength INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS - 75 IU/VIAL Sponsor FERRING Submission history Latest submission status date: 2015-10-27 00:00:00.

Structured Monograph

Clinical summary

Approval overview BRAVELLE is listed in Drugs@FDA under application 021289 (BLA). Review priority: STANDARD Marketing status: Discontinued Active ingredient UROFOLLITROPIN Form and strength INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS - 75 IU/VIAL Sponsor FERRING Submission history Latest submission status date: 2015-10-27 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.